Showing results (191-200 of 365) with videos related to

Sort By:
Pageof 37
Oncology|March 22, 2012
Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancerSilvia Park, Hee Kyung Ahn, Lee Chun Park, et al.
Cancer Research and Treatment|August 4, 2011
Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancerSu Jin Lee, Silvia Park, Hee Kyung Ahn, et al.
Journal of Korean Medical Science|February 16, 2006
Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancerKwang Hyun Paik, Yeon Hee Park, Baek-Yeol Ryoo, et al.
Future Oncology (London, England)|April 18, 2023
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatmentNicholas Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, et al.
Clinical Breast Cancer|January 7, 2016
Limited Supraclavicular Radiation Field in Breast Cancer With ≥ 10 Positive Axillary Lymph NodesJeong Il Yu, Won Park, Doo Ho Choi, et al.
Molecular Cancer Research : MCR|June 17, 2010
Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptorHae Hyun Jung, Yeon Hee Park, Hyun Jung Jun, et al.
Canadian Respiratory Journal|December 27, 2016
Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin AnalogsYeon Hee Park, Chae Uk Chung, Bo Mi Park, et al.
Blood Cancer Journal|December 15, 2021
Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort studyDanbee Kang, Sang Eun Yoon, Dongwook Shin, et al.
Blood|August 20, 2005
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal typeTae Min Kim, Yeon Hee Park, Sang-Yoon Lee, et al.
International Journal of Cancer|February 6, 2019
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patientsJi-Yeon Kim, Eunjin Lee, Kyunghee Park, et al.
Pageof 37